Separately, Henry Schein named a new independent director, Robert Hombach. Hombach formerly served as chief operations officer and chief financial officer of biopharmaceutical firm Baxalta.
NEW YORK, Jan 22 (Reuters) - Activist investor Ananym Capital Management plans to nominate as many as half a dozen directors to the board at Henry Schein (HSIC.O), opens new tab, arguing the ...
Henry Schein (NASDAQ:HSIC ... collaborate with the New York firm to improve shareholder value. Additionally, Robert J. “Bob” Hombach, a former CFO of Baxter (BAX), is also expected to join ...
BofA analyst Allen Lutz double upgraded Henry Schein (HSIC) to Buy from Underperform with a price target of $84, up from $69. The firm believes ...
MELVILLE, N.Y.--(BUSINESS WIRE)-- Henry Schein, Inc. (Nasdaq: HSIC) (“Henry Schein” or the “Company”), the world’s largest provider of health care solutions to office-based dental and ...
NEW YORK (Reuters) - Activist investor Ananym Capital Management plans to nominate as many as half a dozen directors to the board at Henry Schein, arguing the dental and medical distributor needs ...
Hosted on MSN20d
Henry Schein announces KKR investment, prelim. Q4 sales (update)Additionally, Robert J. “Bob” Hombach ... As for preliminary financials, Henry Schein (HSIC) reported $3.2B in revenue and $1.19 of non-GAAP net income per diluted share, compared to $3.34B ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback